Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of ...

While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers ...

The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.

The FDA derives just under half of its yearly funding from pharma user fees, which help support its operations and fund ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...